scholarly journals End-tidal Sevoflurane and Halothane Concentrations during Simulated Airway Occlusion in Healthy Humans

2009 ◽  
Vol 111 (2) ◽  
pp. 287-292 ◽  
Author(s):  
Nick P. Talbot ◽  
Andrew D. Farmery ◽  
Keith L. Dorrington
Keyword(s):  
Minimal Alveolar Concentration ◽  
Healthy Human ◽  
Inhalational Induction ◽  
Sevoflurane Concentration ◽  
Airway Occlusion ◽  
Healthy Humans ◽  
Monoexponential Model ◽  
Body Compartments ◽  
S Period ◽  
End Tidal

Background In a patient whose airway is likely to become obstructed upon loss of consciousness, anesthesia may be induced using an inhaled vapor. If the airway occludes during such an inhalational induction, the speed of patient awakening is related to the rate at which anesthetic gas redistributes away from lung and brain to other body compartments. To determine whether redistribution occurs more rapidly with a more blood-soluble or a less blood-soluble agent, the authors used subanesthetic concentrations of halothane and sevoflurane to simulate inhalational induction and airway obstruction in eight healthy human volunteers. Methods Inhalational induction was simulated using stepwise increases in inspired halothane or sevoflurane concentration, sufficient to reach an end-tidal concentration of approximately 0.1 minimal alveolar concentration. Airway occlusion was then simulated by initiating a 90-s period of rebreathing from a 1-l bag. During rebreathing, end-tidal halothane or sevoflurane concentration was measured continuously by mass spectrometry, and a time constant for the decline in concentration was calculated using a monoexponential model. Results At the onset of rebreathing, end-tidal concentrations of halothane and sevoflurane were 0.10 +/- 0.03 and 0.11 +/- 0.03 minimal alveolar concentration, respectively (mean +/- SD; P > 0.1, Student t test). During rebreathing, the time constants for the decline in end-tidal halothane and sevoflurane concentration were 22 +/- 9 and 62 +/- 16 s, respectively (P < 0.0001). Conclusions During simulated airway occlusion in healthy volunteers, the end-tidal concentration of halothane falls more rapidly than that of sevoflurane. Halothane may therefore lead to more rapid awakening, compared with sevoflurane, should the airway obstruct during an inhalational induction of anesthesia.

Optimum End Tidal Sevoflurane Concentration Required for Intravenous Cannulation in Children

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Bassel Mohamed Essam Noureldin ◽  
Eman Mohamed Kamal Abo Seif ◽  
Omar Mohamed Mohamed Eltawansy ◽  
Mohamed Mohamed Abdel Fattah Ghoneim
Keyword(s):  
Clinical Trial ◽  
Pediatric Patients ◽  
Pediatric Anesthesia ◽  
Healthy Children ◽  
Intravenous Access ◽  
Inhalational Induction ◽  
Sevoflurane Concentration ◽  
Untoward Event ◽  
Inhalation Agent ◽  
End Tidal

Abstract Background Inhalation mask induction is a cornerstone of pediatric anesthesia. Because of their natural aversion to needles, healthy children are usually anesthetized by mask prior to intravenous insertion. The early insertion of an intravenous access provides a means for administering fluids and drugs if an untoward event occurs during inhalational induction. Sevoflurane is the inhalation agent most commonly used for mask inductions in pediatric anesthesia, having largely replaced halothane for this purpose. Objectives The aim of the study was to evaluate the optimum end tidal concentration of Sevoflurane at which an intravenous cannulation can be successfully attempted without movement in pediatric patients. Patients and Methods In this clinical trial, pediatric subjects of either sex aged 2-5 years, weighing 10-20 kg were included. Results Showed that an end tidal sevoflurane of 1.46% has 50% probability for successful intravenous cannulation without movement in children. Conclusion We conclude that an end tidal sevoflurane of 1.46% has 50% probability for successful intravenous cannulation in un- premedicated children aged between 2 and 5 years.

Absence of systematic relationships between REMS duration episodes and spectral power Delta and Ultra-Slow bands in contiguous NREMS episodes in healthy humans

2013 ◽  
Vol 110 (1) ◽  
pp. 162-169 ◽  
Author(s):  
O. Le Bon ◽  
P. Linkowski
Keyword(s):  
Spectral Power ◽  
Sleep Cycle ◽  
Consecutive Series ◽  
Sleep Regulation ◽  
Healthy Human ◽  
Sleep Quantity ◽  
Healthy Humans ◽  
Crucial Component ◽  
Sleep Physiology ◽  
Human Participants

Previous studies in animals and humans have reported correlations between the durations of rapid eye movement sleep (REMS) episodes and immediately preceding or subsequent non-REMS (NREMS) episodes. The relationship between these two types of sleep is a crucial component in understanding the regulation and neurophysiology of ultradian alternations that occur during sleep. Although the present study replicated previous studies, we also measured NREMS in terms of spectral power Delta and Ultra-Slow bands in addition to duration in examining correlations. The spectral power Delta band, also known as slow-wave activity, measures sleep quantity and is believed to reflect sleep physiology better than mere episode durations. The Ultra-Slow spectral power band was analyzed in parallel. Healthy human participants of both sexes ( n = 26, age range 15–45 yr, n = 12 female) were carefully selected to participate in two consecutive series of home polysomnograms performed after 2 nights of habituation to the equipment. In the analyses, REMS episode durations (minutes) were compared with immediately preceding and immediately subsequent NREMS episodes (Delta and Ultra-Slow power) in each sleep cycle. REMS episode duration was more strongly correlated with preceding NREMS episodes than with subsequent NREMS episodes. However, in most cases, no correlations were observed in either direction. One ultradian sleep regulation hypothesis, which is based on stronger correlations between REMS and subsequent NREMS episode durations, holds that the main purpose of REMS is to reactivate NREMS during each sleep cycle. The present results do not support that hypothesis.

scholarly journals Genotypic and Phenotypic Traits That Distinguish Neonatal Meningitis-Associated Escherichia coli from Fecal E. coli Isolates of Healthy Human Hosts

2012 ◽  
Vol 78 (16) ◽  
pp. 5824-5830 ◽  
Author(s):  
Catherine M. Logue ◽  
Curt Doetkott ◽  
Paul Mangiamele ◽  
Yvonne M. Wannemuehler ◽  
Timothy J. Johnson ◽  
...  
Keyword(s):  
Escherichia Coli ◽  
Phylogenetic Group ◽  
Neonatal Meningitis ◽  
Phenotypic Traits ◽  
Healthy Human ◽  
Content Type ◽  
Plasmid Content ◽  
E Coli ◽  
Healthy Humans ◽  
Definition Of

ABSTRACTNeonatal meningitisEscherichia coli(NMEC) is one of the top causes of neonatal meningitis worldwide. Here, 85 NMEC and 204 fecalE. coliisolates from healthy humans (HFEC) were compared for possession of traits related to virulence, antimicrobial resistance, and plasmid content. This comparison was done to identify traits that typify NMEC and distinguish it from commensal strains to refine the definition of the NMEC subpathotype, identify traits that might contribute to NMEC pathogenesis, and facilitate choices of NMEC strains for future study. A large number ofE. colistrains from both groups were untypeable, with the most common serogroups occurring among NMEC being O18, followed by O83, O7, O12, and O1. NMEC strains were more likely than HFEC strains to be assigned to the B2 phylogenetic group. Few NMEC or HFEC strains were resistant to antimicrobials. Genes that best discriminated between NMEC and HFEC strains and that were present in more than 50% of NMEC isolates were mainly from extraintestinal pathogenicE. coligenomic and plasmid pathogenicity islands. Several of these defining traits had not previously been associated with NMEC pathogenesis, are of unknown function, and are plasmid located. Several genes that had been previously associated with NMEC virulence did not dominate among the NMEC isolates. These data suggest that there is much about NMEC virulence that is unknown and that there are pitfalls to studying single NMEC isolates to represent the entire subpathotype.

scholarly journals Capsule Formulation of Ethanolic Extract of Pasak Bumi (Eurycoma Longifolia Jack.,) and its Effect on Human Health Vital Signs

2017 ◽  
Vol 22 (2) ◽  
pp. 91
Author(s):  
Laela Hayu Nurani ◽  
Eka Kumalasari ◽  
Abdul Rohman ◽  
Sitarina Widyarini
Keyword(s):  
Bitter Taste ◽  
Vital Signs ◽  
Ethanolic Extract ◽  
Ethanol Extract ◽  
Inclusion Criteria ◽  
Capsule Formulation ◽  
Healthy Human ◽  
Eurycoma Longifolia ◽  
Healthy Humans ◽  
Eurycoma Longifolia Jack

Pasak bumi (Eurycoma longifolia) has the potential to be developed as antihypertensive, antipyretic, aphrodisiacs and health supplements. The use of E. longifolia as a traditional medicine needs to be pursued in the form of more effective and appropriate formulation. The capsule preparations are easy to make and cancover the bitter taste of E. longifolia. Clinical trials in this study use design pre-post treatment in healthy humans. Subjects used were male - healthy men and healthy women who met inclusion criteria and were subjected with formulated capsule for 14 days. The study resulted capsule formula comprising of the ethanolic extract of E. longifolia 300 mg, vivapur 101 300 mg, 58 mg maydis starch, aerosil 3%, talc 2%, and Mg stearate 1%. The results showed that the capsule of E. longifolia did not affect the value of heart rate, respiration rate, body temperature and weight (P > 0.05), based on paired t-test, but they causes a decrease in blood pressure of healthy human. The ethanol extract of E. longifolia caused vasodilation of blood vessels that can be used in antihypertensive therapy.

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health

2003 ◽  
Vol 284 (1) ◽  
pp. G130-G137 ◽  
Author(s):  
Heather J. Chial ◽  
Michael Camilleri ◽  
Duane Burton ◽  
George Thomforde ◽  
Kevin W. Olden ◽  
...  
Keyword(s):  
Reuptake Inhibitor ◽  
Human Subjects ◽  
Functional Gastrointestinal Disorders ◽  
Gastric Volume ◽  
Colonic Transit ◽  
Selective Serotonin ◽  
Healthy Human ◽  
Double Blind ◽  
Solid Meal ◽  
Healthy Humans

This study evaluated the effects of serotonergic psychoactive agents on gastrointestinal functions in healthy human subjects. Participants received one of four regimens in a randomized, double-blind manner: buspirone, a 5-HT1Areceptor agonist (10 mg twice daily); paroxetine, a selective serotonin reuptake inhibitor (20 mg daily); venlafaxine-XR, a selective serotonin and norepinephrine reuptake inhibitor (75 mg daily); or placebo for 11 days. Physiological testing performed on days 8–11included scintigraphic assessment of gastrointestinal and colonic transit, the nutrient drink test, and assessment of the postprandial change in gastric volume. Fifty-one healthy adults (40 females, 11 males) participated in this study. No effects on gastric emptying or colonic transit were identified with any agent. Small bowel transit of a solid meal was accelerated by paroxetine. Buspirone decreased postprandial aggregate symptom and nausea scores. Venlafaxine-XR increased the postprandial change in gastric volume. Buspirone, paroxetine, and venlafaxine-XR affect upper gastrointestinal functions in healthy humans. These data support the need for clinical and physiological studies of these agents in functional gastrointestinal disorders.

END-TIDAL SEVOFLURANE CONCENTRATION FOR TRACHEAL EXTUBATION (MACex) IN CHILDREN

1998 ◽  
Vol 86 (Supplement) ◽  
pp. 405S
Author(s):  
S. Inomata ◽  
H. Toyooka ◽  
T. Suwa ◽  
S. Sato
Keyword(s):  
Tracheal Extubation ◽  
Sevoflurane Concentration ◽  
End Tidal

scholarly journals Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans

2014 ◽  
Vol 58 (7) ◽  
pp. 3618-3625 ◽  
Author(s):  
Nina V. Malkevich ◽  
Robert J. Hopkins ◽  
Edward Bernton ◽  
Gabriel T. Meister ◽  
Eric M. Vela ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Animal Models ◽  
Half Life ◽  
Healthy Human ◽  
Serious Adverse Events ◽  
Maximum Serum ◽  
Content Type ◽  
Elimination Half Life ◽  
Healthy Humans ◽  
Elimination Half

ABSTRACTAnthrax is an acute infectious disease caused by the spore-forming bacteriumBacillus anthracis. Timely administration of antibiotics approved for the treatment of anthrax disease may prevent associated morbidity and mortality. However, any delay in initiating antimicrobial therapy may result in increased mortality, as inhalational anthrax progresses rapidly to the toxemic phase of disease. An anthrax antitoxin, AVP-21D9, also known as Thravixa (fully human anthrax monoclonal antibody), is being developed as a therapeutic agent against anthrax toxemia. The efficacy of AVP-21D9 inB. anthracis-infected New Zealand White rabbits and in cynomolgus macaques was evaluated, and its safety and pharmacokinetics were assessed in healthy human volunteers. The estimated mean elimination half-life values of AVP-21D9 in surviving anthrax-challenged rabbits and nonhuman primates (NHPs) ranged from approximately 2 to 4 days and 6 to 11 days, respectively. In healthy humans, the mean elimination half-life was in the range of 20 to 27 days. Dose proportionality was observed for the maximum serum concentration (Cmax) of AVP-21D9 and the area under the concentration-time curve (AUC). In therapeutic efficacy animal models, treatment with AVP-21D9 resulted in survival of up to 92% of the rabbits and up to 67% of the macaques. Single infusions of AVP-21D9 were well tolerated in healthy adult volunteers across all doses evaluated, and no serious adverse events were reported. (This study has been registered at ClinicalTrials.gov under registration no. NCT01202695.)

Low O2-induced ATP release from erythrocytes of humans with type 2 diabetes is restored by physiological ratios of C-peptide and insulin

2014 ◽  
Vol 307 (7) ◽  
pp. R862-R868 ◽  
Author(s):  
Jennifer P. Richards ◽  
Gina L. C. Yosten ◽  
Grant R. Kolar ◽  
Cory W. Jones ◽  
Alan H. Stephenson ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Tissue Oxygenation ◽  
Atp Release ◽  
Peripheral Vascular ◽  
Healthy Human ◽  
C Peptide ◽  
Beneficial Effects ◽  
Glucose Levels ◽  
Healthy Humans

ATP release from erythrocytes in response to reduced oxygen (O2) tension stimulates local vasodilation, enabling these cells to direct perfusion to areas in skeletal muscle in need of O2. Erythrocytes of humans with type 2 diabetes do not release ATP in response to low O2. Both C-peptide and insulin individually inhibit low O2-induced ATP release from healthy human erythrocytes, yet when coadministered at physiological concentrations and ratios, no inhibition is seen. Here, we determined: that 1) erythrocytes of healthy humans and humans with type 2 diabetes possess a C-peptide receptor (GPR146), 2) the combination of C-peptide and insulin at physiological ratios rescues low O2-induced ATP release from erythrocytes of humans with type 2 diabetes, 3) residual C-peptide levels reported in humans with type 2 diabetes are not adequate to rescue low O2-induced ATP release in the presence of 1 nM insulin, and 4) the effects of C-peptide and insulin are neither altered by increased glucose levels nor explained by changes in erythrocyte deformability. These results suggest that the addition of C-peptide to the treatment regimen for type 2 diabetes could have beneficial effects on tissue oxygenation, which would help to ameliorate the concomitant peripheral vascular disease.

Sign in / Sign up

Export Citation Format

Share Document